Clinical Research Studies in Pickup Family Neurosciences Institute

Participation in research and clinical investigation is an important commitment of Pickup Family Neurosciences Institute in its mission to provide patients access to leading-edge management and treatment for neurological disorders.

Hoag’s sub-specialized team of neuroscientists are actively involved in research to discover new therapies, drugs and other medical advancements to better the lives of patients suffering from neurological conditions. Pickup Family Neurosciences Institute is currently accepting patients to participate in a number of clinical research trials.

We offer a variety of clinical research studies in the following neurosciences therapeutic areas:

Brain Cancer

• Brain & Nervous System

Memory and Cognitive Disorders

• (190-21) Ph 1, Open-Label Safety Study of Escalating Doses of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous ADSCs in Participants With Mild-Moderate AD Whose Treatment is Not Addressed Adequately by Available Therapy

Stroke

• (211-23) A Phase II, Two-Part, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS) Undergoing Endovascular Thrombectomy (EVT)

• (254-21) A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)

Other

• (113-22) A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo)

• (158-23) A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis

• (190-22) Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis

• (165-24) Open-label Study of Cenobamate Monotherapy in Adult Subjects with Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Your participation in any trial is entirely voluntary. You may decide to withdraw at any time without losing the benefits of your standard medical care.

To learn more about available clinical trials, please contact us at 949-764-4577 or clinicalresearch@hoag.org.